Citations

Clear

4510 citation(s) found for "Scott, C".

Prevalence and Risk Factors of Spondyloarthritis Symptoms in a US-Based Multicenter Cohort of Patients With Inflammatory Bowel Disease
Hong, Simon , Dalal, Rahul S. , Kuhn, Kristine A. , Stahly, Andrew , Scott, Frank I. , Click, Benjamin , Way, Anna, Malik, Fardina , Davis, John M. , Shmais, Manar , Raffals, Laura E., Silfen, Alexa , Dharia, Ishaan , Bhattacharya, Ashish K. , Moghaddam, Bahar, Mains, Trayton, Kurland, Jayde E., Hong, Simon J , Click, Benjamin H , Rubin, David T , Bhattacharya, Abhik , Ermann, Joerg , Jan, Reem , Davis, John M , Silfen, Alexa , Kuhn, Kristine A , Scott, Frank I , Way, Anna, Raffals, Laura E. , Rubin, David T. , Patel, Sheena , Weisman, Michael H. , Ermann, Joerg

Mayo Clinic

American Journal of Gastroenterology | January 6, 2025 | Volume: 120 | Issue: 10 | Pages: 2330-2338

10.14309/ajg.0000000000003292 | PMID 39760386 Get It

INTRODUCTION: Spondyloarthritis (SpA), the most common extraintestinal manifestation of inflammatory bowel disease (IBD), is reported in up to 39% of patients with IBD. Despite this high prevalence, risk factors of developing SpA in patients with IBD are not well described. In this study, we aimed to determine the factors associated with SpA symptoms and their prevalence in an IBD cohort. METHODS: Two validated screening questionnaires for the detection of SpA in IBD (DETAIL = DETection of Arthritis in Inflammatory boweL diseases, IBIS-Q = IBD Identification of Spondyloarthritis Questionnaire) were administered to patients with IBD without a prior diagnosis of SpA in 6 US academic medical centers. Demographic data, IBD characteristics, and medication history were recorded. RESULTS: Screening questionnaires were completed by 588 patients (220 ulcerative colitis, 349 Crohn's disease, and 19 IBD-unclassified), with a median age of 40 years (interquartile range 30–53) and median disease duration of 12 years (interquartile range 6–22). The number of positive screens was 130 (22%) for DETAIL, 196 (33%) for IBIS-Q, and 204 (35%) for either DETAIL or IBIS-Q. Age, female sex, history of smoking, prior bowel surgery, and history of any biologic or targeted small molecule exposure were associated with a positive screen on univariate analysis. After multivariate analysis, female sex (odds ratio [OR] 2.03, 95% confidence interval [CI] 1.41–2.93), older age (OR 1.02, 95% CI 1.01–1.04), history of smoking (OR 1.67, 95% CI 1.04–2.69), and history of any biologic or targeted small molecule exposure (OR 2.27, 95% CI 1.34–3.84) were independently associated with positive screens. Higher number of biologic exposures was associated with higher risk of positive screens, with the highest risk seen with 3 or more exposures (OR 3.25, 95% CI 1.75–6.03). DISCUSSION: A substantial number of patients with IBD screen positive for SpA symptoms, indicating a potentially high burden of undiagnosed illness. Factors associated with SpA symptoms include older age, female sex, and more severe disease (based on increased number of advanced therapies or prior surgery), whereas IBD phenotype does not independently increase the risk of a positive SpA screen. Further studies are needed to confirm these findings and better characterize SpA in IBD.
Procedure Type and Preoperative Patient‐Reported Outcome Metrics Predict Variation in the Value of Hip Arthroscopy for Femoroacetabular Impingement
Dean, Michael C. , Cherian, Nathan J. , LaPorte, Zachary L. , Torabian, Kaveh A. , Dean, Ryan , Martin, Scott D. , Dean, M. Wingerchuk , Torabian, Kaveh A , Etges, Ana Paula Beck da Silva , Dowley, Kieran

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | January 5, 2025 | Volume: 7 | Issue: 2 | Pages: No page available

10.1016/j.asmr.2024.101073 | PMID 40297078 Get It

Purpose To characterize variation in the value of hip arthroscopy for femoroacetabular impingement and explore associations between value and patient‐specific demographic characteristics, comorbidities, preoperative patient‐reported outcome measures (PROMs), and intraoperative variables. Methods We included all patients aged 18 years or older who underwent primary arthroscopic acetabular labral repair or debridement between 2015 and 2020 with minimum 2‐year follow‐up. The exclusion criteria were hip dysplasia, advanced hip osteoarthritis (TÖnnis grade >1), or unreconcilable documenting errors. Value was calculated by dividing 2‐year postoperative International Hip Outcome Tool 33 scores by time‐driven activity‐based costs. To protect the confidentiality of internal hospital cost data, the study average for value was normalized to 100. Multivariable linear mixed‐effects models were used to identify factors underlying variation in value. Results This study included 161 patients. There were 76 women (47.2%) and 85 men, with a mean age of 36.0 years (standard deviation [SD], 10.9 years) and mean body mass index (BMI) of 25.8 (SD, 4.3). Most patients were white (92.5%), were not Hispanic (93.8%), and were commercially insured (92.5%). Preoperatively, 57.1% of hips were classified as Tönnis grade 1 (57.1%) whereas the remainder were grade 0. The normalized value of hip arthroscopy ranged from 25.4 to 216.4 (mean ± SD, 100 ± 38.4), with a 3.0‐fold variation between patients in the 10th and 90th percentiles. Higher value was significantly associated with Tönnis grade 0 (12.2‐point increase, P = .025), no prior contralateral hip arthroscopy (17.3‐point increase, P = .039), higher preoperative PROMs (0.52‐point increase per 1‐unit increase, P < .001), and no bone marrow aspirate concentrate or microfracture (33.8‐point increase, P < .001). Value was also significantly associated with osteoplasty type and labral treatment technique ( P < .05 for both). In contrast, operative year, age, sex, BMI, race, ethnicity, Outerbridge grade, and American Society of Anesthesiologists score were not independently associated with value. A model incorporating these factors as fixed effects and the surgery center as a random effect explained 42.3% of the observed variation in value. Sensitivity analyses revealed that value drivers may vary slightly across PROMs. Conclusions This study revealed wide variation in the value of hip arthroscopy that was most strongly explained by osteoplasty type, labral management technique, and preoperative PROMs. In contrast, patient demographic characteristics such as age, sex, and BMI contributed minimal independent variability. Level of Evidence Level IV, economic and decision analysis.
Integrating Pharmacogenomics into the Broader Construct of Genomic Medicine: Efforts by the ClinGen Pharmacogenomics Working Group (PGxWG)
Gong, Li , Klein, Clarissa , Caudle, Kelly E. , Moyer, Ann M. , Klein, Teri E. , (PGxWG), ClinGen Pharmacogenomics Working Group, Ashcraft, Kristine , Bernhardt, Brooke, Blaxwell, Burns C, Bly, Zo, Cody, Neal, Tredici, Andria L. Del , Gregornik, David , Hart, Jennifer, Hoffman, James M. , Landrum, Melissa , Langlais, Kristofor K., Lee, M T M, Li, Rongling, McLeod, Howard L. , Monte, Andrew A. , Naik, Hetanshi , Obeng, Aniwaa Owusu , Ramos, Erin M. , Ren, Zhaoxia , Ritchie, Marylyn D. , Scherer, Steven E. , Shaaban, Sherin, Swen, Jesse J. , McIntyre, Joanne, Merritt, Keren, Wright, Matt W. , Klein, Teri E , Scott, Stuart A. , Whirl‐Carrillo, Michelle , (PGxWG), ClinGen Pharmacogenomics Working Group, Aminkeng, Folefac , Amr, Sami S , Cipriani, Amber , Dandara, Collet , Empey, Philip E. , Fieg, Elizabeth L. , Gaedigk, Andrea , Harrison, Steven M. , Hunter, Jessica Ezzell , Iwuchukwu, Otito Frances , Malheiro, Adriana , Morales, Joannella , Oni‐Orisan, Akinyemi , Rogers, Sara , Wagner, Alex H. , Woodahl, Erica L , McIntyre, Joanne, Merritt, Keren

Mayo Clinic

Clinical Chemistry | January 3, 2025 | Volume: 71 | Issue: 1 | Pages: 36-44

10.1093/clinchem/hvae181 | PMID 39749515 Get It

Abstract Pharmacogenomics (PGx) is focused on the relationship between an individual's genetic makeup and their response to medications, with the overarching aim of guiding prescribing decisions to improve drug efficacy and reduce adverse events. The PGx and genomic medicine communities have worked independently for over 2 decades, developing separate standards and terminology, making implementation of PGx across all areas of genomic medicine difficult. To address this issue, the Clinical Genome Resource (ClinGen) Pharmacogenomics Working Group (PGxWG) was established by the National Institutes of Health (NIH)-funded ClinGen to initially create frameworks for evaluating gene–drug response clinical validity and actionability aligned with the ClinGen frameworks for evaluating monogenic gene–disease relationships, and a framework for classifying germline PGx variants similar to the American College of Medical Genetics (ACMG) and Association of Molecular Pathology (AMP) system for interpretation of disease-causing variants. These frameworks will leverage decades of work from well-established PGx resources facilitating buy-in among PGx stakeholders. In this report, we describe the background and major activities of the ClinGen PGxWG, and how this initiative will facilitate the critical inclusion of PGx into the larger context of genomic medicine.
Rare genetic variation in fibronectin 1 (FN1) protects against APOE ɛ4 in Alzheimer’s Disease
Uzrek, Bengisu Turgutalp, Reyes‐Dumeyer, Dolly , Jülich, Dörthe , Tayran, Hüseyin, Lantigua, Rafael , Medrano, Martin , Mejía, Diones Rivera , Recio, Patricia, Flaherty, Delaney, Nuriel, Tal , Ertekin‐Taner, Nilüfer , Holley, Scott A. , Mayeux, Richard , Bhattarai, Prabesh , Gunasekaran, Tamil Iniyan , Lee, Annie , Yılmaz, Elanur , Dalgard, Clifton L. , Dickson, Dennis W. , Teich, Andrew F. , Kizil, Caghan , Vardarajan, Badri Narayan

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.089111 Get It

AbstractBackgroundAPOEε4 significantly increases the risk of developing Alzheimer’s disease (AD). Cognitively healthy APOEε4‐carriers exist, suggesting potential protective mechanisms against APOEε4. We hypothesized that some APOEε4‐carriers may have genetic variations protecting them from developing APOEε4‐mediated AD pathology. We aim to identify these protective genetic variants.MethodsWhole genome sequencing (WGS) and cerebrospinal fluid (CSF) proteomics were performed from human cohorts to identify potential protective variants segregating exclusively among APOEε4 carriers. Bioinformatic analyses were performed to select candidate target genes. Immunohistochemistry on postmortem human brain tissues and mouse models expressing human APOE variants were performed along with in‐vivo functional studies in adult zebrafish AD model.ResultWGS analyses revealed 510 potential gene variants segregating exclusively among APOEε4 carriers, which included rare and loss‐of‐function (LOF) variants. Pathway analysis of these genes showed significant enrichment in extracellular matrix (ECM)‐related processes, suggesting protective effects of LOF in ECM proteins. This was further validated by CSF proteome profiling and subsequent analyses in APOEε4 carriers and non‐carriers. Fibronectin‐1 (FN1) and Collagen‐6A2 (COL6A2) were prioritized as candidate target genes for postmortem validation and in‐vivo functional studies. FN1 protein was increased in APOEε4 carriers resulting in thickened ECM at the basement membrane around the blood vessels, potentially impairing pathology‐induced responses such as clearance and immune system activity. This observation is validated in human brains, mouse models and zebrafish model; therefore, the pathological association of FN1 to AD is evolutionarily conserved. Supporting this hypothesis, in‐vivo functional study in zebrafish model with LOF mutations in fn1b revealed that fibronectin LOF enhanced gliovascular remodeling and microglial activation while reducing astrogliosis, suggesting that pathological accumulation of FN1 could impair toxic protein clearance, which is ameliorated with FN1 LOF.ConclusionThe vascular deposition of the ECM components FN1 and COL6A2 are increased in APOEε4 carriers. Rare variant in FN1 protect against APOEε4‐mediated pathogenesis in AD. We propose a new disease mechanisms and potential therapeutic intervention targets for vascular contribution to dementia to mitigate the risk of developing AD.
Longitudinal Neuropsychiatric Symptom Trajectories in Frontotemporal Dementia: From Presymptomatic to Symptomatic Conversion
Scott, Imogene, Chatterjee, Atri , Mackenzie, Ian R. , Huey, Edward D. , Kantarci, Kejal, Rankin, Katherine P. , Rosen, Howard J. , Boxer, Adam L., Lee, Hyun Woo , Lapid, Maria I. , Tartaglia, Maria Carmela , Kantarci, Kejal , Boeve, Bradley F. , Boxer, Adam L. , Hsiung, Ging‐Yuek Robin

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.090036 Get It

AbstractBackgroundFrontotemporal dementia (FTD) presents with heterogeneous neuropsychiatric symptoms (NPS). These symptoms often begin prior to the onset of FTD, and progress throughout the prodromal stages of FTD. Particularly, familial FTD due to autosomal dominant genetic mutations might display mutation‐specific NPS profiles. We hypothesized distinct NPS trajectories for chromosome 9 open reading frame 72 (C9orf72), progranulin (GRN), and microtubule‐associated protein tau (MAPT) mutation carriers during their transition from presymptomatic to symptomatic stages of FTD.MethodIn this study, we analyzed N = 1662 participants from the ARTFL‐LEFFTDS Longitudinal FTLD (ALLFTD) Study, with 342 C9orf72, 148 GRN, 168 MAPT mutation carriers, and 1004 noncarriers. We used the CDR plus NACC FTLD global scores to define the conversion status, and stratified participants into four stages of progression: 1) Presymptomatic (CDR = 0 throughout the follow‐up), 2) Early conversion (began with CDR = 0, then increased to 0.5), 3) Advanced conversion (began with CDR = 0.5, then increased to 1.0 or above), and 4) Symptomatic (CDR>1.0 throughout). Over up to seven visits, the Neuropsychiatric Inventory Questionnaire (NPI‐Q) assessed changes in NPS. We analyzed total NPI‐Q score trajectories using a generalized linear mixed‐effects model, adjusting for age and baseline NPI‐Q scores.ResultOur findings showed similar NPS trajectories among carriers and noncarriers during presymptomatic stages. However, in the early conversion stage, C9orf72 and GRN carriers exhibited significantly higher NPI‐Q score increases compared to MAPT carriers, primarily in the psychosis and hyperactivity domains. In the advanced and symptomatic stages, the rate of increase in NPS was not significantly different across groups.ConclusionThis study suggests that people with familial FTD, particularly those predicted to have underlying TDP‐43 pathology, may experience more severe neuropsychiatric symptoms like psychosis or hyperactivity as they progress from presymptomatic to prodromal phases. This trajectory appears distinct from those with tau pathology or sporadic FTD. Further studies are warranted to understand these unique progression patterns and their implications for FTD management.
Clinical criteria for a limbic‐predominant amnestic neurodegenerative syndrome highly associated with TDP‐43 and slow clinical progression
Graff‐Radford, Jonathan , Przybelski, Scott A. , Wiste, Heather J. , Reichard, Ross R., Fields, Julie A. , Nelson, Peter T. , Lowe, Val J. , Petersen, Ronald C. , Corriveau‐Lecavalier, Nick , Botha, Hugo , Switzer, Aaron , Murray, Melissa E. , Dickson, Dennis W. , Nguyen, Aivi T. , Ramanan, Vijay K. , McCarter, Stuart J. , Boeve, Bradley F. , Machulda, Mary M. , Stricker, Nikki H. , Grothe, Michel J. , Knopman, David S. , Jack, Clifford R. , Jones, David T.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.084087 Get It

AbstractBackgroundLimbic‐predominant age‐related TDP‐43 encephalopathy (LATE) is a neuropathologically‐defined disease, and it is frequently comorbid with Alzheimer’s disease neuropathological change (ADNC). However, the neurological syndrome associated with LATE neuropathological change (LATE‐NC) is not defined. We propose a set of clinical criteria for a limbic‐predominant amnestic neurodegenerative syndrome (LANS) that is highly associated with LATE‐NC. These criteria assess degree of certainty (highest, high, moderate, low) based on features that are measurable in vivo, including older age at evaluation, a mild clinical syndrome, impaired semantic knowledge, disproportionate hippocampal atrophy, limbic hypometabolism, absence of neocortical degeneration patterns and low likelihood of neocortical tau. We operationalized these criteria using two large datasets with clinical and pathologic outcomes.MethodWe screened autopsied patients from Mayo Clinic and ADNI cohorts and applied the LANS criteria to those with an antemortem predominant amnestic syndrome (Mayo, n = 165; ADNI, n = 53). We compared frequencies of neuropathological diagnoses across LANS likelihoods, compared longitudinal CDR‐SB trajectories across LANS likelihoods, and stratified ADNC/LATE‐NC patients according to their LANS likelihood and compared their longitudinal CDR‐SB trajectories to those with ADNC or LATE‐NC.ResultADNC, ADNC/LATE‐NC and LATE‐NC accounted for 35%, 37% and 4% of cases in the Mayo cohort, respectively, and 30%, 22%, and 9% of cases in the ADNI cohort, respectively (Fig. 1). ADNC cases had the lowest LANS likelihoods, LATE‐NC patients had the highest likelihoods, and ADNC/LATE‐NC patients had intermediate likelihoods. Patients with high LANS likelihoods had a milder and slower clinical course and more severe temporo‐limbic degeneration compared to those with low likelihoods (Fig. 2). ADNC/LATE‐NC patients with higher likelihoods had more temporo‐limbic degeneration and a slower rate of cognitive decline, and those with lower likelihoods had more lateral temporo‐parietal degeneration and a faster rate of cognitive decline (Fig. 3).ConclusionThe implementation of LANS criteria has implications for disambiguating the different driving etiologies of progressive amnestic presentations in older age to guide prognosis, treatment, and clinical trial design and enrollment. The development of in vivo biomarkers specific to TDP‐43 pathology are needed to further refine molecular associations between LANS and LATE‐NC and precise antemortem diagnoses of LATE.
Frequency of Spondyloarthritis Symptoms Among US Patients With Inflammatory Bowel Disease: A Cross‐Sectional Multi‐Center Study
Ermann, Joerg , Hong, Simon , Stahly, Andrew , Malik, Fardina , Click, Benjamin , Way, Anna, Davis, John M. , Shmais, Manar, Raffals, Laura E., Silfen, Alexa , Dharia, Ishaan , Bhattacharya, Abhik , Moghaddam, Bahar, Mains, Trayton, Kurland, Jayde E., Weisman, Michael H., Davis, John M , Silfen, Alexa , Kuhn, Kristine A , Ermann, Joerg , Dalal, Rahul S. , Scott, Frank I. , Way, Anna, Raffals, Laura E. , Jan, Reem , Rubin, David T. , Patel, Sheena , Kuhn, Kristine A. , Weisman, Michael H.

Mayo Clinic

Arthritis Care & Research | January 3, 2025 | Volume: 77 | Issue: 6 | Pages: 777-784

10.1002/acr.25493 | PMID 39748206 Get It

ObjectiveSpondyloarthritis (SpA) is the most common extraintestinal manifestation of inflammatory bowel disease (IBD). The application of screening tools to detect SpA in patients with IBD may lead to earlier recognition of SpA and affect treatment decisions.MethodsA combination of two previously described SpA screening questionnaires, the Detection of Arthritis in Inflammatory Bowel Disease (DETAIL) and IBD Identification of Spondyloarthritis Questionnaire (IBIS‐Q), was administered to consecutive patients with IBD attending IBD specialty clinics in six US academic medical centers. Demographic data, IBD, and rheumatology history were extracted by chart review.ResultsA total of 669 patients were analyzed. The median age was 40 years (interquartile range [IQR] 30–54) with a median disease duration of 12 years (IQR 6–22) and moderate to severe IBD based on medication exposure and history of bowel surgery. A total of 81 patients (12%) carried a diagnosis of an inflammatory rheumatic disease, whereas 75 (11%) had consulted a rheumatologist during the previous year. Using published cutoffs, 180 out of 669 patients (27%) screened positive with DETAIL, 266 (40%) with IBIS‐Q, and 275 (41%) with either questionnaire. Axial symptoms were more frequently reported than peripheral musculoskeletal complaints. Notably, 189 out of 275 (69%) screen‐positive patients had neither a documented inflammatory rheumatic disease diagnosis nor a visit with a rheumatologist within the past year.ConclusionA substantial proportion of patients with IBD have symptoms suggestive of SpA, and many of these may have undiagnosed SpA. The IBIS‐Q questionnaire appears to identify more potential SpA cases than DETAIL. Strategies are needed to prioritize rheumatology consultations for those patients with IBD who are most likely to benefit.
Risk of Acute Cholecystitis Based on Combination of Patient Age, Patient Sex, Leukocytosis, and Sonographic Murphy Sign
Patel, Anika G. , Chen, Lea , Young, Scott W. , Dahiya, Nirvikar , Zhang, Nan , Patel, Maitray D , Young, Scott W , Patel, Maitray D.

Mayo Clinic

Journal of Ultrasound in Medicine | January 2, 2025 | Volume: 44 | Issue: 5 | Pages: 807-816

10.1002/jum.16640 | PMID 39745905 Get It

ObjectivesTo combine sonographic Murphy sign (SMS) with clinical parameters to effectively stratify patients into risk groups for acute cholecystitis.MethodsConsecutive emergency department patients from April 1, 2019 to August 31, 2022 with possible acute cholecystitis were grouped using patient age, sex, and white blood cell count to determine the rate of acute cholecystitis found in subgroups. Three distinct clinical risk groups were established and then regrouped by prospective assessment of SMS into three non‐imaging risk groups. Differences in the rate of acute cholecystitis for clinical parameters, clinical risk groups, and non‐imaging risk groups were statistically analyzed.ResultsOf 1231 patients (mean [SD] age, 51.2 [19.5]; 476 [38.7%] male), 156 had acute cholecystitis (mean [SD] age, 62.0 [15.4]; 85 [54.5%] male). Rates differed based on sex (9.4% female vs 17.9% male, P < .001), age group (1.8% for patients <30 years, 9.0% for patients 30–59 years, 22.3% for patients ≥60 years; P < .001), and white blood cell count (23.1% elevated vs 6.6% not elevated; P < .001). The low, average, and high non‐imaging risk groups had acute cholecystitis rates of 1.8%, 14.0%, and 43.1%, respectively. Relative risk (95% CI) for the low non‐imaging group compared with others was 0.07 (0.04, 0.12; P < .001); relative risk for the high non‐imaging risk group compared with others was 7.05 (5.32, 9.43; P < .001).ConclusionsSonographic Murphy sign assessment combined with patient age, sex, and white blood cell count effectively stratifies acute care patients into distinct acute cholecystitis risk groups.
Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Hwang, Justin H. , Likasitwatanakul, Pornlada , Deshmukh, Sachin Kumar , Wu, Sharon , Kwon, Jason J. , Toye, Eamon , Moline, David , Evans, Mark G. , Elliott, Andrew , Passow, Rachel , Luo, Christine , John, Emily , McKay, Rana R. , Heath, Elisabeth I. , Nabhan, Chadi , Reizine, Natalie , Orme, Jacob J. , Domingo‐Domenech, Josep , Dehm, Scott M. , Hwang, Justin H , Gandhi, Nishant , McKay, Rana R , Heath, Elisabeth I , Nabhan, Chadi , Reizine, Natalie , Orme, Jacob J , Domingo Domenech, Josep M , Sartor, A Oliver , Baca, Sylvan C , Dehm, Scott M , Antonarakis, Emmanuel S , Elliott, Andrew , Gandhi, Nishant , Sartor, Oliver , Antonarakis, Emmanuel S.

Mayo Clinic

Clinical Cancer Research | January 2, 2025 | Volume: 31 | Issue: 5 | Pages: 936-948

10.1158/1078-0432.ccr-24-3471 | PMID 39745364 Get It

Abstract Purpose: Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1, whereby the alteration type and the effect on the forkhead (FKH) domain affect protein function. We developed a FOXA1 classification system to inform clinical management. Experimental Design: A total of 5,014 prostate cancer samples were examined using whole-exome and -transcriptome sequencing from the Caris Life Sciences database. We denoted class 1 FOXA1 alterations as missense and in-frame insertions/deletions with subclasses oriented with respect to the FKH domain. These were in the first part of the FKH domain [class 1A: amino acids (AA) 168–246], within the Wing2 region of FKH (class 1B: AA 247–269), or outside FKH (class 1C: AA 1–167, 270+). Two hotspot missense mutations at R219 were denoted class 2. Class 3 included predicted truncating mutations with subclasses partitioned based on the FKH domain (class 3A: AA 1–269 and class 3B: AA 270+). Class 4 represented FOXA1 amplifications. Real-world overall survival and therapy outcomes were determined from insurance claims. Results: FOXA1 alterations did not influence survival when considered in aggregate but had distinct prognostic effects when stratified by class. In primary prostate samples, class 1A alterations were associated with overall improved survival (HR, 0.57; P = 0.03); a similar trend was seen in metastatic biopsies with class 1B (HR, 0.84; P = 0.09). Conversely, in primary specimens, class 1C exhibited worse survival upon second-generation androgen receptor signaling inhibitor treatment (HR, 1.93; P &lt; 0.001). Class 2 mutations (R219C/S) were enriched in neuroendocrine prostate cancers and were associated with overall poor survival (HR, 2.05; P &lt; 0.001) and worse outcomes to first-line androgen-deprivation therapies (HR, 2.5; P &lt; 0.001). Class 3A alterations indicated improved survival (HR, 0.70; P = 0.01), whereas class 3B alterations portended poor outcomes (HR, 1.50; P &lt; 0.001). Amplifications (class 4) indicated poor outcomes in metastatic samples (HR, 1.48; P = 0.02). Molecularly, different FOXA1 alteration classes harbored distinct mutational and immunologic features as well as unique transcriptional programs. Finally, relative to European Americans, African Americans had increased class 1C alterations, whereas Asian/Pacific Islander patients had increased class 1B alterations. Conclusions: FOXA1 alterations should not be interpreted in aggregate, as different classes are associated with divergent molecular features and clinical outcomes. Our revised classification schema facilitates clinical decision-making for patients with prostate cancer and uncovers important racial differences.
Common Questions and Misconceptions About Energy Drinks: What Does the Scientific Evidence Really Show?
António, José , Antonio, Brandi , Arent, Shawn M. , Candow, Darren G. , Escalante, Guillermo , Evans, Cassandra , Forbes, Scott C. , Fukuda, David H. , Gibbons, Maureen, Jagim, Andrew R. , Kerksick, Chad M. , Kurtz, Jennifer A. , Lillis, Joseph , Lowery, Lonnie , Mastrofini, Gianna F. , Mills, Scotty, Nelson, Michael T. , Pereira, Flavia , Roberts, Justin , Sagner, Michael , Stout, Jeffrey R. , Wells, Adam J. , Forbes, Scott C , Fukuda, David , Jagim, Andrew R , Kerksick, Chad M , Kurtz, Jennifer A , Lowery, Lonnie , Mastrofini, Gianna F , Pereira, Flavia , Roberts, Justin , Stout, Jeffrey R , Wells, Adam , Antonio, Jose , Arent, Shawn M , Harty, Patrick S. , Kalman, Douglas , Tartar, Jaime L.

Mayo Clinic

Nutrients | January 1, 2025 | Volume: 17 | Issue: 1 | Pages: 67

10.3390/nu17010067 | PMID 39796501 Get It

Energy drinks are a commonly consumed beverage, and studies suggest a possible performance-enhancing effect. A Google Scholar search using the keywords “energy drinks” and “exercise” yields numerous results, underscoring the voluminous research on this topic. However, there are questions regarding the effectiveness and safety of energy drinks. These questions include, but are not limited to: (1) What are the main active ingredients in energy drinks? (2) Do energy drinks assist in weight management? (3) Do energy drinks enhance aerobic performance? (4) Do energy drinks enhance athletic speed? (5) Do energy drinks improve reaction time? (6) Do energy drinks enhance lean tissue mass? (7) Can energy drinks improve cognitive performance? (8) Does the acute consumption of energy drinks elevate resting energy expenditure? (9) Is there any evidence to suggest that energy drinks are more effective than an identical serving of caffeine alone? (10) Are there sex differences in the response to energy drink consumption? (11) Do energy drinks affect sleep or sleepiness? (12) Should pregnant women avoid energy drinks? (13) Do energy drinks adversely affect cardiovascular function? (14) Does consuming energy drinks cause brain damage? (15) What are other safety considerations regarding energy drinks? (16) Is there any evidence to suggest that energy drinks are more effective than an identical serving of caffeine alone? (17) If caffeine is the main active ingredient in energy drinks and coffee, why is there a discrepancy in the adverse events reported for each? To address these questions, we performed an evidence-based scientific evaluation of the literature on energy drink supplementation.